Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Womb transplant: a temporary fix for a permanent infertility?

NCT ID NCT05646992

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study tests whether a temporary uterus transplant from a living donor can allow women with uterine factor infertility—who lack a functioning uterus—to become pregnant and deliver a healthy baby. Recipients receive immunosuppressive drugs to prevent rejection, and the uterus is removed after childbirth. The trial involves about 40 participants and follows recipients for up to five years, with children followed into adulthood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Uterus transplantation from a living donor, with immunosuppressive drugs (tacrolimus and azathioprine) to prevent rejection.
What this could lead to
If successful, this could offer a path to pregnancy and childbirth for women born without a functioning uterus, using a temporary transplant.
What could go wrong
This is an early-stage surgical procedure with risks from major surgery and immunosuppression; success is not guaranteed and the uterus is removed after childbirth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Feb 2043

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 38 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA - Recipient Inclusion Criteria: * Genotypic female of any race, color, or ethnicity. * Uterine factor infertility. * Aged 18-38 years at time of egg retrieval. * Strong desire to undergo uterus transplant in order to become pregnant and give birth to a child. * Embryo cryopreservation with embryos located at Johns Hopkins: * Has a minimum of 4-8 cryopreserved normal embryos following Preimplantation Genetic Screening (PGS-screening). OR o Is willing to undergo egg retrieval, in vitro fertilization, and PGS-screening to cryopreserve a minimum of 4-8 normal embryos. * Willingness to undergo embryo implantation after uterus transplantation to achieve pregnancy. * In the opinion of the study team, makes a reasonable effort to identify and refer her own potential uterus donor to the study team. * Completes the protocol informed consent form. * Non-smoker, defined by having never smoked or having quit \>6 consecutive months prior to screening. * No co-existing medical condition which, in the opinion of the study team, could affect the immunosuppression protocol, surgical procedure, or ability to be pregnant or bear a child. (See Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of uterus transplantation.) * Negative serum pregnancy test. * Blood type compatible with donor. * Negative crossmatch with donor. * Patient agrees to comply with the protocol and states a dedication to the treatment regime. * Agrees to uterus explanation following birth of a child and or 5 years without successful pregnancy. Donor Inclusion Criteria: * Genotypic female with an intact uterus. * Medical history includes known successful pregnancy (e.g., gravid uterus). * Aged 25 - 65 years. * Consents to uterus donation and required pre-donation screening. * For females of child-bearing potential: Negative serum pregnancy test. * Blood type compatible with recipient. * Negative crossmatch with recipient. Donor and Recipient Inclusion Criteria: * USA citizen or equivalent. * No co-existing psycho-social problems (i.e., alcoholism, drug abuse). * BMI ≤35 o A higher BMI may be accepted at the discretion of the study team. * Negative for HIV at transplant. * Negative for malignancy for past 5 years. EXCLUSION CRITERIA- Donor and Recipient Exclusion Criteria: * Positive for any of the following conditions: * Insulin-dependent diabetes mellitus. * Untreated sepsis. * HIV (active or seropositive). * Active tuberculosis. * Active Hepatitis B infection. * Active Hepatitis C infection. * Viral encephalitis. * Toxoplasmosis. * Current/recent (within 3 months of donation/screening consent) IV drug abuse. * Significant cardiac disease * Significant vascular disease o * Sensitized recipients with high levels (50%) of panel-reactive Human Leukocyte Antigens (HLA) antibodies. * Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc. * Mixed connective tissue diseases and collagen diseases that can result in poor wound healing after surgery. * Severe neurologic deficits. * Patients considered unsuitable per the consulted Psychiatric/Psychologic appraisal. * A history of medical non-compliance. Donor Only Exclusion Criteria: * Previous injury to the uterus including giving birth by Cesarean section. * History of radiation therapy to the abdominal area. * Other medical conditions, as determined by the study physicians, that would preclude donation. Recipient Only Exclusion Criteria: • Conditions that, in the opinion of the study team, may expose the recipient to unacceptable risks under immunosuppressive treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uterine factor infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins University School of Medicine

    RECRUITING

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.